BATM Advanced Communications Ltd (LON:BVC)

BATM Advanced Communications Ltd (LON:BVC)


Share Price
46.95 p
Change
1.1 (2.40 %)
Market Cap
£189.61 m
Proactive Investors - Run By Investors For Investors

BATM Advanced Communications Ltd RNS Release

Receipt of $14.5m investment in Ador Diagnostics


RNS Number : 2141V
BATM Advanced Communications Ld
05 April 2019
 

LEI: 213800FLQUB9J289RU66

 

5 April 2019

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Receipt of $14.5m investment in Ador Diagnostics

First instalment under Investment Agreement to advance molecular diagnostics solution

                                                                                                                                     

Further to the announcement of 28 January 2019, BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce the completion of the initial investment of $14.5m ("Initial Investment") under the conditional subscription and shareholders' agreement (the "Investment Agreement") for up to $30m to provide additional funds for the commercialisation of the molecular biology-based solutions being developed by Ador Diagnostics.

 

Pursuant to the Investment Agreement, following the Initial Investment, Ador Diagnostics has an enterprise value of $44.5m and BATM has an ownership interest of 38.2%.

 

A further $15.5m (at a valuation that will be a 33.3% premium to the post-Initial Investment enterprise valuation) is expected to be funded by the end of 2020, subject to certain milestones being achieved.

 

Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are delighted to have received the Initial Investment to accelerate the commercialisation of our breakthrough NATlab system, which we believe will revolutionise the point-of-care medical diagnostics industry. Since signing the Investment Agreement, we have continued to make progress in our final preparations ahead of in-hospital installation. We are very excited about the tremendous potential of this unique molecular biology-based diagnostics solution."

 

 

Enquiries:

 

BATM Advanced Communications


Dr. Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer




Shore Capital Stockbrokers Limited (Broker to the Group)


Mark Percy, Anita Ghanekar

+44 20 7408 4050



SPARK Advisory Partners Limited (Financial Adviser to the Group)


Mark Brady, Andrew Emmott

+44 20 3368 3550



Luther Pendragon (Financial PR)


Harry Chathli, Claire Norbury, Joe Quinlan

+44 20 7618 9100

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBIGDSRDGBGCS

BATM Advanced Communications Ltd Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use